Summary:
- The FDA has approved Isembyld (apitegromab), a novel monoclonal antibody therapy specifically designed to target myostatin, representing a significant advancement in the treatment of Spinal Muscular Atrophy (SMA).
- This therapy functions by inhibiting myostatin—a protein that limits muscle growth—thereby promoting muscle mass and strength, offering a new therapeutic mechanism beyond existing SMN-enhancing treatments for patients with SMA.